D Ross Camidge Selected Research

Biomarkers (Surrogate Marker)

7/2022	Phase I study of PT-112, a novel pyrophosphate-platinum immunogenic cell death inducer, in advanced solid tumours.
1/2022	Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial.
7/2021	A narrative review of primary research endpoints of neoadjuvant therapy for lung cancer: past, present and future.
10/2020	Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer.
1/2019	Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC.
8/2017	Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
1/2017	Drinking Not Drowning: How to Deal With the Deluge of Potential Predictive Biomarker Approaches in Non-Small-Cell Lung Cancer.
1/2016	Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
6/2014	FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies.
6/2012	Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

D Ross Camidge Research Topics

Disease

116	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 11/2006
77	Neoplasms (Cancer) 02/2024 - 09/2007
42	Lung Neoplasms (Lung Cancer) 02/2024 - 07/2007
23	Disease Progression 01/2023 - 09/2009
16	Brain Neoplasms (Brain Tumor) 02/2024 - 06/2015
14	Neoplasm Metastasis (Metastasis) 12/2023 - 01/2016
14	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 03/2011
7	Fatigue 01/2021 - 09/2009
5	Thrombocytopenia (Thrombopenia) 01/2021 - 09/2009
5	Central Nervous System Diseases (CNS Diseases) 01/2021 - 10/2015
4	Pneumonia (Pneumonitis) 01/2022 - 12/2016
4	Dyspnea (Shortness of Breath) 01/2021 - 06/2013
4	Nausea 01/2021 - 08/2007
4	Sarcoma (Soft Tissue Sarcoma) 01/2019 - 09/2012
4	Adenocarcinoma 01/2018 - 11/2008
3	Diarrhea 11/2021 - 03/2014
3	Vomiting 01/2021 - 08/2007
3	Neutropenia 01/2019 - 09/2009
3	Adenocarcinoma of Lung 01/2018 - 02/2015
2	Melanoma (Melanoma, Malignant) 12/2023 - 03/2010
2	Thymoma (Thymic Carcinoma) 07/2022 - 01/2017
2	Interstitial Lung Diseases (Interstitial Lung Disease) 01/2022 - 08/2020
2	Chronic Renal Insufficiency 01/2019 - 03/2014
2	Neuroblastoma 01/2016 - 02/2015
2	Alopecia (Baldness) 06/2013 - 09/2009
1	Dysgeusia (Parageusia) 01/2024
1	Dizziness (Lightheadedness) 01/2024
1	Paresthesia (Dysesthesia) 01/2024
1	Ovarian Neoplasms (Ovarian Cancer) 12/2023
1	Bradycardia 02/2023

Drug/Important Bio-Agent (IBA)

55	CrizotinibIBA 12/2022 - 10/2010
31	Tyrosine Kinase InhibitorsIBA 02/2024 - 07/2010
31	Anaplastic Lymphoma KinaseIBA 12/2022 - 12/2009
23	ErbB Receptors (EGF Receptor)IBA 01/2024 - 11/2008
16	brigatinibIBA 12/2022 - 08/2017
12	alectinibIBA 02/2023 - 02/2016
12	Biomarkers (Surrogate Marker)IBA 07/2022 - 03/2011
10	Phosphotransferases (Kinase)IBA 01/2018 - 12/2010
8	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2023 - 09/2011
7	Carboplatin (JM8)FDA LinkGeneric 01/2019 - 08/2008
6	Immune Checkpoint InhibitorsIBA 12/2022 - 01/2019
6	Pemetrexed (MTA)FDA Link 10/2015 - 04/2011
5	Circulating Tumor DNAIBA 02/2024 - 01/2019
5	PlatinumIBA 12/2023 - 06/2013
5	Proteins (Proteins, Gene)FDA Link 10/2023 - 03/2011
5	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2018 - 11/2014
5	Paclitaxel (Taxol)FDA LinkGeneric 10/2014 - 08/2008
5	Monoclonal AntibodiesIBA 05/2014 - 08/2008
4	Immunoconjugates (Immunoconjugate)IBA 11/2021 - 08/2017
4	osimertinibIBA 01/2021 - 12/2016
4	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 10/2016
4	rociletinibIBA 11/2018 - 04/2015
3	durvalumabIBA 01/2023 - 10/2022
3	NivolumabIBA 01/2021 - 01/2020
3	navitoclaxIBA 01/2021 - 03/2011
3	CreatinineIBA 01/2019 - 09/2011
3	lorlatinibIBA 01/2019 - 12/2018
3	Sunitinib (Sutent)FDA Link 10/2018 - 02/2013
3	AfatinibIBA 01/2018 - 09/2014
3	Transaminases (Aminotransferases)IBA 01/2017 - 06/2013
3	RamucirumabIBA 03/2015 - 02/2010
3	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 02/2010 - 07/2007
2	repotrectinibIBA 01/2024 - 10/2018
2	telisotuzumab vedotinIBA 10/2023 - 11/2021
2	Cell-Free Nucleic AcidsIBA 01/2022 - 11/2018
2	Proto-Oncogene Proteins c-metIBA 01/2022 - 01/2017
2	human ERBB2 proteinIBA 08/2020 - 02/2015
2	Focal Adhesion Protein-Tyrosine KinasesIBA 01/2020 - 05/2012
2	Alanine Transaminase (SGPT)IBA 01/2020 - 10/2012
2	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 01/2019 - 01/2017
2	Messenger RNA (mRNA)IBA 01/2019 - 06/2014
2	LigandsIBA 01/2019 - 05/2014
2	ponatinibIBA 01/2019 - 06/2014
2	Gefitinib (Iressa)FDA Link 11/2017 - 09/2014
2	Cetuximab (Erbitux)FDA Link 11/2017 - 09/2014
2	sacituzumab govitecanIBA 10/2017 - 08/2017
2	ceritinibIBA 04/2016 - 03/2014
2	dacomitinibIBA 01/2016 - 04/2014
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2015 - 02/2010
2	mapatumumabIBA 05/2014 - 09/2009
2	Testosterone (Sustanon)FDA Link 07/2013 - 11/2012
2	Peptides (Polypeptides)IBA 06/2012 - 03/2011
2	big gastrinIBA 06/2012 - 03/2011
2	Immunoglobulin G (IgG)IBA 02/2012 - 02/2010
2	CaspasesIBA 11/2010 - 09/2010
2	Insulin-Like PeptidesIBA 07/2009 - 08/2008
1	pembrolizumabIBA 02/2024
1	Cytotoxins (Cytolysins)IBA 01/2024
1	DepsipeptidesIBA 12/2023
1	Histone Deacetylase InhibitorsIBA 12/2023
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2023
1	binimetinibIBA 12/2023
1	Histone Deacetylases (Histone Deacetylase)IBA 12/2023
1	tremelimumabIBA 01/2023
1	sotorasibIBA 01/2023
1	Pregnenolone Carbonitrile (PCN)IBA 11/2022

Therapy/Procedure

59	Therapeutics 02/2024 - 11/2006
23	Drug Therapy (Chemotherapy) 02/2024 - 07/2007
18	Radiotherapy 01/2023 - 11/2006
7	Immunotherapy 01/2023 - 12/2017